The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium.
作者： Adriaan Blommaert , Joke Bilcke , Lander Willem , Jan Verhaegen , Herman Goossens
DOI: 10.1016/J.VACCINE.2016.03.003
关键词:
摘要: Abstract Background A recent trial demonstrated the 13 valent conjugate pneumococcal vaccine (PCV13) to be effective against invasive and non-invasive disease in healthy adults. PCV13 might therefore considered as an alternative 23 polysaccharide (PPV23). Aim To explore cost-effectiveness of vaccinating adults over 50, with either or PPV23 alone, a combined strategy using both PPV23. Methods static multi-cohort model was developed simulating consequences vaccination 50 from health care payer's perspective, for different scenarios duration protection serotype evolution. Results At currently expected prices, is unlikely cost-effective compared no combination versus only. Conclusion Further research needed on efficacy risk groups, well protection. Serotype evolutions under influence childhood PCV program should closely monitored.
core.ac.uk 
sci-hub.se 参考文章(24)
Mark J Sculpher, Karl Claxton, Andrew Briggs, Decision Modelling for Health Economic Evaluation ,(2006)
S Dirmesropian, JG Wood, CR MacIntyre, AT Newall, A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly Human Vaccines & Immunotherapeutics. ,vol. 11, pp. 818- 825 ,(2015) , 10.1080/21645515.2015.1011954
Marie-Josée J. Mangen, Mark H. Rozenbaum, Susanne M. Huijts, Cornelis H. van Werkhoven, Douwe F. Postma, Mark Atwood, Anna M.M. van Deursen, Arie van der Ende, Diederick E. Grobbee, Elisabeth A.M. Sanders, Reiko Sato, Theo J.M. Verheij, Conrad E. Vissink, Marc J.M. Bonten, G. Ardine de Wit, Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. European Respiratory Journal. ,vol. 46, pp. 1407- 1416 ,(2015) , 10.1183/13993003.00325-2015
Zitta B. Harboe, Reimar W. Thomsen, Anders Riis, Palle Valentiner-Branth, Jens Jørgen Christensen, Lotte Lambertsen, Karen A. Krogfelt, Helle B. Konradsen, Thomas L. Benfield, Pneumococcal Serotypes and Mortality following Invasive Pneumococcal Disease: A Population-Based Cohort Study PLOS Medicine. ,vol. 6, ,(2009) , 10.1371/JOURNAL.PMED.1000081
Alessia Melegaro, Alessia Melegaro, The 23-Valent Pneumococcal Polysaccharide Vaccine. Part I. Efficacy of PPV in the Elderly: A Comparison of Meta-Analyses European Journal of Epidemiology. ,vol. 19, pp. 353- 363 ,(2003) , 10.1023/B:EJEP.0000024701.94769.98
Joke Bilcke, Albert Jan van Hoek, Philippe Beutels, Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting? Human Vaccines & Immunotherapeutics. ,vol. 9, pp. 812- 822 ,(2013) , 10.4161/HV.23334
Germaine Hanquet, Tinne Lernout, Anne Vergison, Jan Verhaegen, Esther Kissling, David Tuerlinckx, Anne Malfroot, Béatrice Swennen, Martine Sabbe, Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine. ,vol. 29, pp. 2856- 2864 ,(2011) , 10.1016/J.VACCINE.2011.02.016
A Melegaro, WJ Edmunds, None, Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. ,vol. 22, pp. 4203- 4214 ,(2004) , 10.1016/J.VACCINE.2004.05.003
Joke Bilcke, Christiaan Marais, Benson Ogunjimi, Lander Willem, Niel Hens, Philippe Beutels, Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium Vaccine. ,vol. 30, pp. 675- 684 ,(2012) , 10.1016/J.VACCINE.2011.10.036
Pauline A Waight, Nicholas J Andrews, Shamez N Ladhani, Carmen L Sheppard, Mary P E Slack, Elizabeth Miller, Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study Lancet Infectious Diseases. ,vol. 15, pp. 535- 543 ,(2015) , 10.1016/S1473-3099(15)70044-7